Eliquis Market Overview
The Eliquis Market was valued at USD 3.83 billion in 2024 and is expected to grow from USD 4.02 billion in 2025 to USD 6.5 billion by 2035, registering a CAGR of 5.0% during the 2026–2035 forecast period. Market growth is being supported by the increasing prevalence of atrial fibrillation and venous thromboembolism, a growing aging population, rising awareness of anticoagulant therapies, and increasing preference for oral anticoagulants.
North America is expected to remain the leading regional market, with a value of USD 1.76 billion in 2024 and a projected value of USD 2.88 billion by 2035. Europe is also an important market, while Asia-Pacific is emerging as a significant growth region as healthcare investment, disease awareness, and access to anticoagulant therapies increase.
Unlock Exclusive Insights – Request Your Free Sample Report Now!
https://www.wiseguyreports.com/sample-request?id=568924
Key Companies in the Eliquis Market
Regeneron Pharmaceuticals
AstraZeneca
Boehringer Ingelheim
Merck & Co
Gilead Sciences
Hemispherx Biopharma
Mylan
AbbVie
Sanofi
Roche
Amgen
Bristol Myers Squibb
Pfizer
Novartis
Johnson & Johnson
The Eliquis Market is primarily driven by the rising incidence of atrial fibrillation and other thromboembolic disorders. Growing awareness of stroke prevention and the convenience of oral anticoagulant therapy are supporting adoption. The expanding geriatric population is another important factor, as older adults have a higher incidence of cardiovascular and thromboembolic conditions. Opportunities are also emerging from improved healthcare access in developing markets, personalized medicine, telehealth, and advances in drug delivery.
The market is segmented by indication, formulation, distribution channel, patient type, and region. Indications include Atrial Fibrillation, Deep Vein Thrombosis, Pulmonary Embolism, and Postoperative Thromboprophylaxis. The Atrial Fibrillation segment was valued at USD 1.5 billion in 2024 and is projected to reach USD 2.45 billion by 2035. Formulations include Oral Tablets and Injection, while distribution channels comprise Hospitals, Pharmacies, and Online Pharmacy. Patient types include Adult, Geriatric, and Pediatric populations.
Recent Developments and Market Trends:
Pfizer announced an expansion of Eliquis manufacturing capacity in March 2025 to support growing demand and improve supply availability.
Bristol Myers Squibb disclosed a commercial collaboration with major U.S. payers in May 2025 aimed at broadening Eliquis formulary coverage and improving patient access.
Merck & Co. announced a collaboration in July 2025 focused on evaluating next-generation anticoagulant candidates.
Growing preference for oral anticoagulants is supporting the adoption of convenient patient-centric treatment options.
Personalized medicine and digital health technologies are creating opportunities for improved treatment management and patient monitoring.
Increasing clinical research into anticoagulant therapies is supporting broader awareness and use across different patient populations.
Reasons to Buy the Report:
Understand the market size, growth rate, and forecast outlook of the global Eliquis Market.
Analyze major indications including atrial fibrillation, deep vein thrombosis, pulmonary embolism, and postoperative thromboprophylaxis.
Evaluate formulation opportunities across oral tablets and injections.
Assess distribution channels including hospitals, pharmacies, and online pharmacies.
Identify leading companies and understand the competitive landscape.
Examine regional growth opportunities across North America, Europe, Asia-Pacific, South America, and the Middle East and Africa.
Understand the impact of aging populations, cardiovascular disease prevalence, personalized medicine, and digital healthcare on future market growth.
Future Outlook:
The Eliquis Market is expected to maintain steady growth through 2035 as the prevalence of atrial fibrillation and venous thromboembolism continues to rise. Increasing awareness of stroke prevention, an expanding geriatric population, and preference for convenient oral anticoagulant therapies should support demand. Greater healthcare access in emerging markets, personalized treatment approaches, telehealth, and continued pharmaceutical innovation are expected to create additional opportunities for market expansion.
➤➤Explore Our Latest Related Reports:
